2. Academic Validation
  3. N-Alkyl Carbamoylimidazoles as Versatile Synthons for the Synthesis of Urea-Based PSMA Inhibitors

N-Alkyl Carbamoylimidazoles as Versatile Synthons for the Synthesis of Urea-Based PSMA Inhibitors

  • ACS Med Chem Lett. 2023 Jun 9;14(7):943-948. doi: 10.1021/acsmedchemlett.3c00087.
Narendar Reddy Gade 1,  Jatinder Kaur 1,  Atul Bhardwaj 1,  Edris Ebrahimi 1,  Jennifer Dufour 1,  Melinda Wuest 1,  Frank Wuest 1 2 3
Affiliations

Affiliations

  • 1 Department of Oncology, University of Alberta, Edmonton, Alberta T6G 1Z2, Canada.
  • 2 Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta T6G 2H1, Canada.
  • 3 Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2R3, Canada.
PMID: 37465305 DOI: 10.1021/acsmedchemlett.3c00087
Abstract

We describe N-alkyl carbamoylimidazoles as readily available and highly versatile synthons for synthesizing urea-based prostate-specific membrane antigen (PSMA) inhibitors. Urea formation proceeded in high yields (>80%) at room temperature under aqueous conditions. All novel compounds were tested for their PSMA inhibitory potency in a cell-based radiometric binding assay. Compound 17 was identified as a novel high-affinity PSMA Inhibitor (IC50 = 0.013 μM) suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate Cancer.

Figures
Products